Profile data is unavailable for this security.
About the company
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
- Revenue in USD (TTM)0.00
- Net income in USD-125.55m
- Incorporated2016
- Employees128.00
- LocationPrelude Therapeutics Inc175 Innovation BoulevardWILMINGTON 19805United StatesUSA
- Phone+1 (302) 467-1280
- Fax+1 (302) 658-3989
- Websitehttps://preludetx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aldeyra Therapeutics Inc | 0.00 | -30.01m | 193.10m | 10.00 | -- | 1.70 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
Chromadex Corp | 83.17m | -3.53m | 194.89m | 106.00 | -- | 6.70 | -- | 2.34 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 195.13m | 140.00 | -- | 25.23 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
2Seventy Bio Inc | 71.20m | -223.22m | 198.42m | 274.00 | -- | 0.9565 | -- | 2.79 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Akebia Therapeutics Inc | 187.23m | -43.03m | 201.21m | 167.00 | -- | -- | -- | 1.07 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.34 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 83.44 | 69.13 | -22.98 | -82.25 | 1.31 | -4.82 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
AVITA Medical Inc | 50.70m | -44.82m | 203.30m | 207.00 | -- | 6.24 | -- | 4.01 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Codexis Inc | 74.23m | -65.13m | 203.91m | 174.00 | -- | 2.57 | -- | 2.75 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Prelude Therapeutics Inc | 0.00 | -125.55m | 204.89m | 128.00 | -- | 0.7447 | -- | -- | -1.88 | -1.88 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 207.29m | 49.00 | -- | 4.67 | -- | 2,559.17 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Skye Bioscience Inc | 0.00 | -37.50m | 212.19m | 11.00 | -- | 2.69 | -- | -- | -4.50 | -4.50 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -75.43 | -232.67 | -101.00 | -- | -- | -- | -- | -- | -- | -46.11 | 0.0552 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Fractyl Health Inc | 148.00k | -83.16m | 212.66m | 102.00 | -- | 2.53 | -- | 1,436.91 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
Q32 Bio Inc | 354.00k | -83.09m | 215.56m | 39.00 | -- | 4.42 | -- | 608.91 | -25.73 | -25.73 | 0.1182 | 4.09 | 0.002 | -- | -- | 50,571.43 | -34.17 | -34.98 | -40.05 | -37.92 | -- | -- | -16,901.98 | -971.76 | -- | -- | 0.2039 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Rezolute Inc | 0.00 | -58.21m | 216.32m | 51.00 | -- | 2.38 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Gossamer Bio Inc | 0.00 | -172.58m | 217.12m | 135.00 | -- | 8.13 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Baker Bros. Advisors LPas of 14 Jun 2024 | 10.12m | 24.05% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.01m | 2.39% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 927.54k | 2.20% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 925.13k | 2.20% |
Massachusetts Financial Services Co.as of 31 Mar 2024 | 508.15k | 1.21% |
Geode Capital Management LLCas of 31 Mar 2024 | 361.63k | 0.86% |
Sio Capital Management LLCas of 31 Mar 2024 | 320.39k | 0.76% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 244.95k | 0.58% |
Renaissance Technologies LLCas of 31 Mar 2024 | 244.80k | 0.58% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 211.44k | 0.50% |